Cargando…

Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment

BACKGROUND: (18)F-flortaucipir PET received FDA approval to visualize aggregated neurofibrillary tangles (NFTs) in brains of adult patients with cognitive impairment being evaluated for Alzheimer’s disease (AD). However, manufacturer’s guidelines for visual interpretation of (18)F-flortaucipir PET d...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Charles D., Ponisio, Maria Rosana, Lang, Jordan A., Flores, Shaney, Schindler, Suzanne E., Fagan, Anne M., Morris, John C., Benzinger, Tammie L.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200228/
https://www.ncbi.nlm.nih.gov/pubmed/37092225
http://dx.doi.org/10.3233/JAD-230032
_version_ 1785045096685633536
author Chen, Charles D.
Ponisio, Maria Rosana
Lang, Jordan A.
Flores, Shaney
Schindler, Suzanne E.
Fagan, Anne M.
Morris, John C.
Benzinger, Tammie L.S.
author_facet Chen, Charles D.
Ponisio, Maria Rosana
Lang, Jordan A.
Flores, Shaney
Schindler, Suzanne E.
Fagan, Anne M.
Morris, John C.
Benzinger, Tammie L.S.
author_sort Chen, Charles D.
collection PubMed
description BACKGROUND: (18)F-flortaucipir PET received FDA approval to visualize aggregated neurofibrillary tangles (NFTs) in brains of adult patients with cognitive impairment being evaluated for Alzheimer’s disease (AD). However, manufacturer’s guidelines for visual interpretation of (18)F-flortaucipir PET differ from how (18)F-flortaucipir PET has been measured in research settings using standardized uptake value ratios (SUVRs). How visual interpretation relates to (18)F-flortaucipir PET SUVR, cerebrospinal fluid (CSF) biomarkers, or longitudinal clinical assessment is not well understood. OBJECTIVE: We compare various diagnostic methods in participants enrolled in longitudinal observational studies of aging and memory (n = 189, 23 were cognitively impaired). METHODS: Participants had tau PET, Aβ PET, MRI, and clinical and cognitive evaluation within 18 months (n = 189); the majority (n = 144) also underwent lumbar puncture. Two radiologists followed manufacturer’s guidelines for (18)F-flortaucipir PET visual interpretation. RESULTS: Visual interpretation had high agreement with SUVR (98.4%)and moderate agreement with CSF p-tau181 (86.1%). Two participants demonstrated (18)F-flortaucipir uptake from meningiomas. Visual interpretation could not predict follow-up clinical assessment in 9.52% of cases. CONCLUSION: Visual interpretation was highly consistent with SUVR (discordant participants had hemorrhagic infarcts or occipital-predominant AD NFT deposition) and moderately consistent with CSF p-tau181 (discordant participants had AD pathophysiology not detectable on tau PET). However, close association between AD NFT deposition and clinical onset in group-level studies does not necessarily hold at the individual level, with discrepancies arising from atypical AD, vascular dementia, or frontotemporal dementia. A better understanding of relationships across imaging, CSF biomarkers, and clinical assessment is needed to provide appropriate diagnoses for these individuals.
format Online
Article
Text
id pubmed-10200228
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-102002282023-05-22 Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment Chen, Charles D. Ponisio, Maria Rosana Lang, Jordan A. Flores, Shaney Schindler, Suzanne E. Fagan, Anne M. Morris, John C. Benzinger, Tammie L.S. J Alzheimers Dis Research Article BACKGROUND: (18)F-flortaucipir PET received FDA approval to visualize aggregated neurofibrillary tangles (NFTs) in brains of adult patients with cognitive impairment being evaluated for Alzheimer’s disease (AD). However, manufacturer’s guidelines for visual interpretation of (18)F-flortaucipir PET differ from how (18)F-flortaucipir PET has been measured in research settings using standardized uptake value ratios (SUVRs). How visual interpretation relates to (18)F-flortaucipir PET SUVR, cerebrospinal fluid (CSF) biomarkers, or longitudinal clinical assessment is not well understood. OBJECTIVE: We compare various diagnostic methods in participants enrolled in longitudinal observational studies of aging and memory (n = 189, 23 were cognitively impaired). METHODS: Participants had tau PET, Aβ PET, MRI, and clinical and cognitive evaluation within 18 months (n = 189); the majority (n = 144) also underwent lumbar puncture. Two radiologists followed manufacturer’s guidelines for (18)F-flortaucipir PET visual interpretation. RESULTS: Visual interpretation had high agreement with SUVR (98.4%)and moderate agreement with CSF p-tau181 (86.1%). Two participants demonstrated (18)F-flortaucipir uptake from meningiomas. Visual interpretation could not predict follow-up clinical assessment in 9.52% of cases. CONCLUSION: Visual interpretation was highly consistent with SUVR (discordant participants had hemorrhagic infarcts or occipital-predominant AD NFT deposition) and moderately consistent with CSF p-tau181 (discordant participants had AD pathophysiology not detectable on tau PET). However, close association between AD NFT deposition and clinical onset in group-level studies does not necessarily hold at the individual level, with discrepancies arising from atypical AD, vascular dementia, or frontotemporal dementia. A better understanding of relationships across imaging, CSF biomarkers, and clinical assessment is needed to provide appropriate diagnoses for these individuals. IOS Press 2023-05-16 /pmc/articles/PMC10200228/ /pubmed/37092225 http://dx.doi.org/10.3233/JAD-230032 Text en © 2023 – The authors. Published by IOS Press https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) License (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Chen, Charles D.
Ponisio, Maria Rosana
Lang, Jordan A.
Flores, Shaney
Schindler, Suzanne E.
Fagan, Anne M.
Morris, John C.
Benzinger, Tammie L.S.
Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment
title Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment
title_full Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment
title_fullStr Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment
title_full_unstemmed Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment
title_short Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment
title_sort comparing tau pet visual interpretation with tau pet quantification, cerebrospinal fluid biomarkers, and longitudinal clinical assessment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200228/
https://www.ncbi.nlm.nih.gov/pubmed/37092225
http://dx.doi.org/10.3233/JAD-230032
work_keys_str_mv AT chencharlesd comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment
AT ponisiomariarosana comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment
AT langjordana comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment
AT floresshaney comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment
AT schindlersuzannee comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment
AT faganannem comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment
AT morrisjohnc comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment
AT benzingertammiels comparingtaupetvisualinterpretationwithtaupetquantificationcerebrospinalfluidbiomarkersandlongitudinalclinicalassessment